BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Promising Results from CyberAgrot Study

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an innovative agriculture biotech company focused on providing natural biological protection for high value crops, recently released potentially industry-changing results for its initial Colombia laboratory test. The study evaluated the effect of its proprietary mustard-derived organic biopesticide formulation on the disease Fusarium wilt TR4. MustGrow’s study, conducted and reported via third-party laboratory CyberAgrot SAS in Colombia using Instituto Colombiano Agropecuario (“ICA”) official protocols, reported 100% control of the disease. A recent article discussing this reads, “In the announcement, MustGrow outlined the CyberAgrot study results. Carefully adhering to ICA official protocols, the test evaluated samples treated with MustGrow’s natural organic biopesticide as well as control samples that were left untreated. The study tested five different rates, and all data was measured after a five-day period. In all samples, MustGrow’s biopesticide showed 100% control of Fusarium wilt TR4. By contrast, all of the control samples showed Fusarium wilt TR4 still growing.”

To view the full article, visit https://ibn.fm/VcoAo

About MustGrow Biologics Corp

MustGrow is a publicly traded agriculture biotech company focused on providing natural science-based biological solutions for high value crops, including fruits and vegetables. MustGrow has designed and owns a United States EPA-approved natural solution that uses the mustard seed’s natural defense mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada’s PMRA (Pest Management Regulatory Agency) as a bio-pesticide for high value crops such as in fruit and vegetables. MustGrow has now concentrated a liquid format, TerraMG, which, with regulatory approval, could be applied through standard drip or spray equipment, improving functionality and performance features. For more information, visit the company’s website at www.MustGrow.ca.

NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Featured in BioMedWire Editorial on Real-Time Intoxication Detection Technologies

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid…

23 minutes ago

BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Receives 2026 Healthcare Innovation Award for Drug Resistance Research

Kairos Pharma (NYSE American: KAPA) announced it has been named a winner in the 2026…

43 minutes ago

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Advances Commercial Launch, Reports First-Quarter 2026 Results

HeartBeam (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results highlighted by the launch of…

1 hour ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces First Patient Dosed in Phase 1b Trial of Sapu003

Oncotelic Therapeutics (OTCQB: OTLC), alongside Sapu Nano, announced that the first patient has been dosed in the Phase 1b clinical trial…

23 hours ago

BioMedNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation

This article has been disseminated on behalf of SureNano Science Ltd. and may include paid…

1 day ago

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Next-Generation CNS Drug Delivery

Oncotelic Therapeutics (OTCQB: OTLC) was featured in BioMedWire editorial coverage examining the growing urgency around…

1 day ago